{"hands_on_practices": [{"introduction": "The diagnosis of schizophreniform disorder hinges on rigorously applying the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) duration criteria. This exercise [@problem_id:4756646] moves beyond simple symptom recognition to test your ability to construct and interpret a clinical timeline, a foundational skill in psychiatric assessment. By working through a hypothetical but clinically realistic case with fluctuating symptoms, you will practice summing the continuous duration of prodromal, active, and residual phases to determine if the disorder's temporal boundaries—at least one month but less than six months—are met.", "problem": "A $24$-year-old graduate student with no prior psychotic history presents with a $2$-month trajectory of fluctuating symptoms. The onset was insidious with social withdrawal, decreased academic productivity, and blunted affect without mood congruent features. The course is reconstructed via a collateral-verified timeline, with careful distinction between acute positive symptoms (delusions, hallucinations, grossly disorganized speech or behavior) versus residual negative symptoms (avolition, alogia, flat affect) and impaired functioning. There is no evidence of a major mood episode meeting full criteria, repeated urine toxicology screens are negative, and neurological workup is unrevealing. The patient has no sustained period of full return to premorbid functioning during the interval described.\n\nTimeline segments:\n- Prodromal phase with clear functional decline and negative symptoms: $14$ days.\n- Acute positive symptom episode $1$ (delusions and auditory hallucinations): $10$ days.\n- Partial remission with residual negative symptoms (no delusions/hallucinations, persistent social withdrawal and avolition): $12$ days.\n- Acute positive symptom episode $2$: $9$ days.\n- Partial remission with residual negative symptoms: $11$ days. During this interval, there is a brief $3$-day span of minimal subjective symptoms, but objective blunted affect and functional impairment remain; there is no full return to baseline.\n- Acute positive symptom episode $3$: $10$ days.\n- Residual phase (attenuated thought blocking, flat affect, persistent functional decline): $13$ days.\n\nAssume all acute episodes meet Criterion A for schizophrenia spectrum disorders (at least two core psychotic symptoms, including delusions or hallucinations), and that residual phases contain persistent negative symptoms and impaired functioning without full remission. Based on accepted diagnostic conventions for schizophrenia spectrum disorders (as codified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)), determine whether the duration threshold for schizophreniform disorder is satisfied and select the single best interpretation of the timeline.\n\nWhich option is most accurate?\n\nA. The continuous disturbance, counting prodromal and residual periods, totals $79$ days, which is $\\geq 1$ month and $ 6$ months; this meets the duration threshold for schizophreniform disorder.\n\nB. Only days with overt delusions or hallucinations are counted; the acute psychosis totals $29$ days ($10+9+10$), which is $ 1$ month; therefore this is recurrent brief psychotic disorder rather than schizophreniform disorder.\n\nC. Inter-episode remissions prevent summation; because each acute episode is $ 1$ month, the threshold is not met, regardless of residual symptoms.\n\nD. The prodromal and residual phases cannot be applied toward duration; the total continuous disturbance exceeds $6$ months once those phases are excluded, making schizophrenia the correct diagnosis.", "solution": "The problem statement is subjected to validation before proceeding to a solution.\n\n### Step 1: Extract Givens\n\n-   Patient age: $24$ years old.\n-   Prior history: No prior psychotic history.\n-   Total symptom trajectory: $2$ months.\n-   Symptom onset: Insidious, with social withdrawal, decreased academic productivity, and blunted affect without mood congruent features.\n-   Clinical verification: Collateral-verified timeline.\n-   Exclusions: No major mood episode meeting full criteria; repeated urine toxicology screens are negative; neurological workup is unrevealing.\n-   Remission status: No sustained period of full return to premorbid functioning.\n\nTimeline segments:\n-   Prodromal phase (functional decline, negative symptoms): $14$ days.\n-   Acute positive symptom episode $1$ (delusions, hallucinations): $10$ days.\n-   Partial remission (residual negative symptoms, no delusions/hallucinations): $12$ days.\n-   Acute positive symptom episode $2$: $9$ days.\n-   Partial remission (residual negative symptoms, brief subjective improvement but objective impairment): $11$ days.\n-   Acute positive symptom episode $3$: $10$ days.\n-   Residual phase (attenuated thought blocking, flat affect, functional decline): $13$ days.\n\nAssumptions:\n-   Acute episodes meet Criterion A for schizophrenia spectrum disorders.\n-   Residual phases contain persistent negative symptoms and impaired functioning without full remission.\n\nQuestion: Based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) conventions, determine if the duration threshold for schizophreniform disorder is met and select the single best interpretation.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientifically Grounded**: The problem is based on the application of the DSM-5, which is the standard classification system for psychiatric disorders used in the United States and many other parts of the world. While psychiatric nosology is subject to ongoing research and debate, its application as a formal system with explicit rules is a valid basis for a deductive problem. The problem is grounded in the established principles of clinical psychiatry.\n-   **Well-Posed**: The problem provides a detailed timeline and a clear, objective standard for evaluation (DSM-5 criteria). It asks for a specific determination (whether the duration threshold is met) based on these data and rules. A unique, stable solution is derivable.\n-   **Objective**: The problem uses precise clinical terminology (e.g., \"blunted affect,\" \"avolition,\" \"delusions\") and quantifies the timeline. It explicitly references an external, objective standard (DSM-5), removing subjective interpretation from the core task.\n\nThe problem does not exhibit any of the enumerated flaws. It is not factually unsound, is formalizable within its domain, is complete and consistent, is clinically realistic, and is well-structured.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation\n\nThe central principle for solving this problem is the duration criterion for Schizophreniform Disorder as specified in the DSM-5. The relevant criterion is Criterion B, which states that an episode of the disorder (including prodromal, active, and residual phases) must last at least $1$ month but less than $6$ months. The DSM-5 explicitly clarifies that the total duration of the disturbance is calculated by summing the lengths of the prodromal, active, and residual periods, provided these phases are continuous without a full return to premorbid functioning.\n\nThe problem statement indicates a \"continuous disturbance\" with no \"full return to premorbid functioning.\" Therefore, the total duration of the illness is the sum of all specified timeline segments.\n\nLet $T_{total}$ represent the total duration of the disturbance in days. The individual segments are:\n-   $T_{prodromal} = 14$ days\n-   $T_{acute,1} = 10$ days\n-   $T_{remission,1} = 12$ days\n-   $T_{acute,2} = 9$ days\n-   $T_{remission,2} = 11$ days\n-   $T_{acute,3} = 10$ days\n-   $T_{residual} = 13$ days\n\nThe total duration is the sum of these periods:\n$$T_{total} = T_{prodromal} + T_{acute,1} + T_{remission,1} + T_{acute,2} + T_{remission,2} + T_{acute,3} + T_{residual}$$\n$$T_{total} = 14 + 10 + 12 + 9 + 11 + 10 + 13$$\n$$T_{total} = 79 \\text{ days}$$\n\nAccording to DSM-5, the duration threshold for schizophreniform disorder is $\\geq 1$ month and $ 6$ months. Using the standard approximation of $30$ days for $1$ month:\n-   Duration of $1$ month $\\approx 30$ days.\n-   Duration of $6$ months $\\approx 180$ days.\n\nThe calculated total duration is $T_{total} = 79$ days. We must now check if this value satisfies the condition:\n-   Is $79 \\text{ days} \\geq 1 \\text{ month}$? Yes, $79 > 30$.\n-   Is $79 \\text{ days}  6 \\text{ months}$? Yes, $79  180$.\n\nThe total duration of the continuous disturbance is $79$ days, which satisfies the duration criteria for schizophreniform disorder.\n\n### Option-by-Option Analysis\n\n**A. The continuous disturbance, counting prodromal and residual periods, totals $79$ days, which is $\\geq 1$ month and $ 6$ months; this meets the duration threshold for schizophreniform disorder.**\nThis option correctly identifies the rule for calculating the duration of the disturbance by including all phases (prodromal, active, and residual/partial remission) because there was no return to baseline functioning. The calculation, $14+10+12+9+11+10+13 = 79$ days, is accurate. The conclusion that $79$ days is between $1$ month and $6$ months is also correct. This interpretation is fully consistent with DSM-5 criteria.\nVerdict: **Correct**.\n\n**B. Only days with overt delusions or hallucinations are counted; the acute psychosis totals $29$ days ($10+9+10$), which is $ 1$ month; therefore this is recurrent brief psychotic disorder rather than schizophreniform disorder.**\nThis option is based on a false premise. The DSM-5 duration criterion for schizophreniform disorder explicitly includes prodromal and residual phases, not just the periods of active psychosis. The calculation of the acute phases ($10+9+10 = 29$ days) is arithmetically correct, but its application is diagnostically invalid. Furthermore, a diagnosis of brief psychotic disorder (or recurrent brief psychotic disorder) requires a full return to premorbid functioning after an episode, which is explicitly contradicted by the problem statement (\"no sustained period of full return to premorbid functioning\").\nVerdict: **Incorrect**.\n\n**C. Inter-episode remissions prevent summation; because each acute episode is $ 1$ month, the threshold is not met, regardless of residual symptoms.**\nThis option is fundamentally incorrect. The periods described as \"partial remission\" are not periods of wellness; they are characterized by persistent residual negative symptoms and functional impairment. As such, they are part of a single, continuous episode of illness. The concept of \"inter-episode remission\" only applies if there is a full return to premorbid functioning, which is ruled out in the problem. The duration of the entire continuous disturbance is what matters, not the duration of individual acute flares.\nVerdict: **Incorrect**.\n\n**D. The prodromal and residual phases cannot be applied toward duration; the total continuous disturbance exceeds $6$ months once those phases are excluded, making schizophrenia the correct diagnosis.**\nThis option contains multiple errors. First, as established, the premise that prodromal and residual phases are excluded from the duration calculation is false. Second, the assertion that the duration exceeds $6$ months is factually incorrect; the total duration is $79$ days, which is less than $3$ months. Therefore, neither the reasoning nor the conclusion is valid.\nVerdict: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4756646"}, {"introduction": "A critical step following initial diagnosis is the differential diagnosis, particularly distinguishing a primary psychotic disorder from a substance-induced mimic. This practice [@problem_id:4756561] provides a quantitative framework for this common clinical challenge using Bayes' theorem. You will learn how to formally update your diagnostic certainty by integrating pre-test probabilities with the results of a diagnostic test, transforming an intuitive process into a rigorous, evidence-based calculation.", "problem": "A psychiatry team evaluates a $24$-year-old with a first episode of psychosis. After a comprehensive medical work-up, the differential has been narrowed to two mutually exclusive and collectively exhaustive etiologies: substance-induced psychosis (denoted $S$) and primary schizophreniform disorder (denoted $P$), consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Based on epidemiologic data adjusted for this patient’s demographic and clinical context, the team assigns prior probabilities $P(S) = 0.35$ and $P(P) = 0.65$. A point-of-care urine drug screen (UDS) immunoassay that targets recent amphetamine and cocaine exposure has operating characteristics at psychotogenic exposure thresholds: sensitivity $0.90$ for detecting substance exposure sufficient to induce psychosis and specificity $0.95$ against false positives in the absence of such exposure. The UDS result is positive. Using the definition of conditional probability and the law of total probability as your fundamental base, derive the posterior probability that the current psychosis is due to primary schizophreniform disorder, $P(P \\mid +)$, where $+$ denotes a positive UDS. Express your final answer as a simplified exact fraction. No units are required, and do not use a percentage sign.", "solution": "The problem as stated is scientifically grounded, well-posed, objective, and contains all necessary information for a unique solution. It is a direct application of Bayesian probability theory to a realistic clinical scenario in psychiatry. Therefore, the problem is deemed valid and a formal solution can be constructed.\n\nLet $S$ denote the event that the patient's psychosis is substance-induced, and let $P$ denote the event that the psychosis is due to primary schizophreniform disorder. The problem states these two etiologies are mutually exclusive and collectively exhaustive. Let $+$ denote the event of a positive result on the urine drug screen (UDS).\n\nThe problem provides the following prior probabilities based on epidemiologic data:\n$$P(S) = 0.35$$\n$$P(P) = 0.65$$\nAs a check for consistency, $P(S) + P(P) = 0.35 + 0.65 = 1.00$, which is required for a set of mutually exclusive and collectively exhaustive events.\n\nThe operating characteristics of the UDS are provided. The sensitivity of the test is the probability of a positive result given that the condition (substance exposure sufficient to cause psychosis) is present. This corresponds to $P(+ \\mid S)$.\n$$P(+ \\mid S) = 0.90$$\nThe specificity of the test is the probability of a negative result given that the condition is absent. In this diagnostic framework, the absence of substance-induced psychosis is equivalent to the presence of primary schizophreniform disorder. Let $-$ denote a negative test result.\n$$\\text{Specificity} = P(- \\mid P) = 0.95$$\n\nWe are tasked with deriving the posterior probability of primary schizophreniform disorder given that the UDS result is positive, which is denoted as $P(P \\mid +)$.\n\nTo solve this, we employ Bayes' theorem. The theorem is derived from the fundamental definition of conditional probability, which states:\n$$P(A \\mid B) = \\frac{P(A \\cap B)}{P(B)}$$\nApplying this definition to our problem, we have:\n$$P(P \\mid +) = \\frac{P(P \\cap +)}{P(+)}$$\nThe numerator, $P(P \\cap +)$, is the joint probability of having primary schizophreniform disorder and testing positive. It can be re-written using the definition of conditional probability as:\n$$P(P \\cap +) = P(+ \\mid P) P(P)$$\nThe denominator, $P(+)$, is the total probability of obtaining a positive test result. This can be calculated using the law of total probability, summing over the partition of the sample space formed by the mutually exclusive and exhaustive events $S$ and $P$:\n$$P(+) = P(+ \\cap S) + P(+ \\cap P)$$\n$$P(+) = P(+ \\mid S) P(S) + P(+ \\mid P) P(P)$$\nSubstituting these expressions for the numerator and denominator back into our equation for $P(P \\mid +)$ gives the full form of Bayes' theorem for this problem:\n$$P(P \\mid +) = \\frac{P(+ \\mid P) P(P)}{P(+ \\mid S) P(S) + P(+ \\mid P) P(P)}$$\nWe have been given $P(P)$, $P(S)$, and $P(+ \\mid S)$. We must first calculate $P(+ \\mid P)$. Since a test result can only be positive or negative for any given state, the probabilities must sum to $1$:\n$$P(+ \\mid P) + P(- \\mid P) = 1$$\nUsing the given specificity, $P(- \\mid P) = 0.95$, we can find $P(+ \\mid P)$, which represents the false positive rate:\n$$P(+ \\mid P) = 1 - P(- \\mid P) = 1 - 0.95 = 0.05$$\nNow we can substitute all the numerical values into the Bayesian formula:\n$$P(P \\mid +) = \\frac{(0.05)(0.65)}{(0.90)(0.35) + (0.05)(0.65)}$$\nWe proceed with the arithmetic calculation.\nFirst, the numerator:\n$$0.05 \\times 0.65 = 0.0325$$\nNext, the terms in the denominator:\n$$0.90 \\times 0.35 = 0.3150$$\n$$0.05 \\times 0.65 = 0.0325$$\nSumming the terms in the denominator:\n$$0.3150 + 0.0325 = 0.3475$$\nThus, the posterior probability is the ratio:\n$$P(P \\mid +) = \\frac{0.0325}{0.3475}$$\nTo express this value as a simplified exact fraction as requested, we can multiply the numerator and denominator by $10000$ to eliminate the decimal points:\n$$P(P \\mid +) = \\frac{325}{3475}$$\nNow, we simplify this fraction. We can observe that both numbers are divisible by $25$.\n$$325 = 25 \\times 13$$\n$$3475 = 25 \\times 139$$\nThus, the fraction simplifies to:\n$$P(P \\mid +) = \\frac{25 \\times 13}{25 \\times 139} = \\frac{13}{139}$$\nThe number $13$ is a prime number. To confirm the fraction is fully simplified, we must check if $139$ is a multiple of $13$. Since $13 \\times 10 = 130$ and $13 \\times 11 = 143$, $139$ is not a multiple of $13$. Therefore, the fraction $\\frac{13}{139}$ is in its simplest form.", "answer": "$$\\boxed{\\frac{13}{139}}$$", "id": "4756561"}, {"introduction": "Effective treatment requires translating neurobiological theory into precise clinical action. This advanced problem [@problem_id:4756580] bridges pharmacodynamics and pharmacokinetics to guide antipsychotic dosing. You will use a mass-action model of receptor binding and a pharmacokinetic model to calculate the specific oral dose of a medication required to achieve a target dopamine $D_2$ receptor occupancy, demonstrating how modern psychopharmacology aims to optimize efficacy while minimizing side effects.", "problem": "A patient with schizophreniform disorder presents with a first-episode psychosis, and the clinical goal is to titrate a dopamine D2 receptor ($D_2$) antagonist to an average steady-state receptor occupancy consistent with minimizing extrapyramidal symptoms (EPS) while achieving antipsychotic efficacy. Assume a simple equilibrium binding scenario at the $D_2$ receptor consistent with the law of mass action, and a one-compartment pharmacokinetic model with linear clearance. Consider oral haloperidol dosed once daily. Use the following scientifically plausible parameters, which are treated as constants:\n- Target average steady-state receptor occupancy $RO^{*} = 0.65$.\n- Dopamine $D_2$ equilibrium dissociation constant $K_{d} = 1.5\\,\\text{nM}$ for haloperidol.\n- Oral bioavailability $F = 0.60$.\n- Systemic clearance $\\text{Cl} = 9\\,\\text{L/h}$.\n- Dosing interval $\\tau = 24\\,\\text{h}$.\n- Molecular weight $\\text{MW} = 375\\,\\text{g/mol}$ for haloperidol.\n- Plasma unbound fraction $f_{u,p} = 0.12$.\n- Unbound brain-to-plasma ratio at the receptor site $K_{p,uu} = 1.0$.\nAssume that the average steady-state unbound brain concentration at the receptor site equals the average steady-state unbound brain extracellular fluid concentration, which is the product of the plasma total concentration, the plasma unbound fraction, and the unbound brain-to-plasma ratio. Assume once-daily dosing achieves a steady-state average plasma concentration given by a linear one-compartment model, and ignore peak–trough fluctuation and active metabolites for the purpose of this calculation.\n\nUsing these assumptions and the equilibrium framework implied by the law of mass action, determine the once-daily oral dose $D$ (in $\\text{mg/day}$) that yields the target average steady-state $D_2$ receptor occupancy $RO^{*}$. Express your final answer in $\\text{mg/day}$ and round to four significant figures.\n\nIn addition to performing the calculation, your solution must explicitly justify, from first principles, how receptor occupancy at the site relates to the plasma concentration and why occupancy in the range implied by $RO^{*}$ is used to guide dosing decisions in first-episode psychosis in schizophreniform disorder. The final numerical answer must be presented as specified above.", "solution": "The problem is subjected to validation before proceeding with a solution.\n\n### Step 1: Extract Givens\n- Target average steady-state receptor occupancy: $RO^{*} = 0.65$\n- Dopamine D2 equilibrium dissociation constant for haloperidol: $K_{d} = 1.5\\,\\text{nM}$\n- Oral bioavailability: $F = 0.60$\n- Systemic clearance: $\\text{Cl} = 9\\,\\text{L/h}$\n- Dosing interval: $\\tau = 24\\,\\text{h}$\n- Molecular weight of haloperidol: $\\text{MW} = 375\\,\\text{g/mol}$\n- Plasma unbound fraction: $f_{u,p} = 0.12$\n- Unbound brain-to-plasma ratio at the receptor site: $K_{p,uu} = 1.0$\n- Assumptions:\n    1.  Simple equilibrium binding governed by the law of mass action.\n    2.  A one-compartment pharmacokinetic model with linear clearance.\n    3.  Once-daily oral dosing of haloperidol.\n    4.  Average steady-state unbound brain concentration at the receptor site ($C_{u,brain,ss,avg}$) is given by $C_{u,brain,ss,avg} = C_{p,ss,avg} \\times f_{u,p} \\times K_{p,uu}$, where $C_{p,ss,avg}$ is the average steady-state total plasma concentration.\n    5.  $C_{p,ss,avg}$ is described by the linear one-compartment model for oral dosing.\n    6.  Peak–trough fluctuations and active metabolites are disregarded.\n- Required Output: The once-daily oral dose $D$ in $\\text{mg/day}$, rounded to four significant figures.\n- Additional Requirement: Justify the relationship between plasma concentration and receptor occupancy, and the clinical rationale for the target occupancy $RO^{*}$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is well-founded in the principles of pharmacokinetics (PK) and pharmacodynamics (PD). The use of the law of mass action to model receptor binding, the one-compartment PK model for drug disposition, and the concepts of clearance, bioavailability, and protein binding are standard in pharmacology. The specified target occupancy of $RO^{*} = 0.65$ for a D2 antagonist reflects established clinical knowledge derived from neuroimaging studies (e.g., PET scans), which correlate occupancy levels with antipsychotic efficacy and the risk of extrapyramidal symptoms (EPS). The given parameters for haloperidol are scientifically plausible.\n- **Well-Posed**: The problem is fully specified, providing all necessary constants and simplifying assumptions to permit a direct calculation. It defines a clear objective ($D$) and provides an unambiguous mathematical pathway to connect the inputs to the output. A unique solution exists.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically sound, well-posed, objective, and contains no contradictions or ambiguities. A complete solution will be provided.\n\n### Conceptual Justification\n\n1.  **Relationship between Plasma Concentration and Receptor Occupancy**:\n    The interaction between a drug (ligand, $L$) and its receptor ($R$) to form a drug-receptor complex ($LR$) can be described at equilibrium by the law of mass action:\n    $$L + R \\rightleftharpoons LR$$\n    The equilibrium dissociation constant, $K_d$, is defined as the ratio of the product of the concentrations of the reactants to the concentration of the product at equilibrium:\n    $$K_d = \\frac{[L][R]}{[LR]}$$\n    where $[L]$, $[R]$, and $[LR]$ are the molar concentrations of the free ligand, free receptor, and ligand-receptor complex, respectively. Receptor occupancy ($RO$) is the fraction of total receptors ($R_T = [R] + [LR]$) that are bound by the ligand:\n    $$RO = \\frac{[LR]}{R_T} = \\frac{[LR]}{[R] + [LR]}$$\n    By rearranging the $K_d$ expression, we find $[R] = \\frac{K_d [LR]}{[L]}$. Substituting this into the $RO$ equation yields:\n    $$RO = \\frac{[LR]}{\\frac{K_d [LR]}{[L]} + [LR]} = \\frac{1}{\\frac{K_d}{[L]} + 1} = \\frac{[L]}{K_d + [L]}$$\n    This is the Hill-Langmuir equation, which directly relates the concentration of the free ligand at the receptor site, $[L]$, to the fractional receptor occupancy. In this problem, the free ligand concentration at the receptor site is the average steady-state unbound concentration in the brain, $C_{u,brain,ss,avg}$. This concentration is linked to the systemic circulation by assuming it is a function of the average steady-state total plasma concentration, $C_{p,ss,avg}$, as specified:\n    $$[L] = C_{u,brain,ss,avg} = C_{p,ss,avg} \\times f_{u,p} \\times K_{p,uu}$$\n    Therefore, the receptor occupancy is directly dependent on the average total plasma concentration, which is in turn controlled by the dosing regimen.\n\n2.  **Clinical Rationale for Target Occupancy $RO^{*} = 0.65$**:\n    The therapeutic action of antipsychotic drugs like haloperidol is primarily mediated by their antagonism of dopamine $D_2$ receptors in specific brain pathways, which is believed to ameliorate the positive symptoms of psychosis. However, antagonism of these same receptors in other pathways, such as the nigrostriatal pathway, can lead to adverse motor side effects known as extrapyramidal symptoms (EPS), including parkinsonism, dystonia, and akathisia. Positron Emission Tomography (PET) studies in patients have established a \"therapeutic window\" for $D_2$ receptor occupancy. Clinical efficacy is generally observed when occupancy exceeds a threshold of approximately $60\\%$. Conversely, the risk of EPS increases sharply when occupancy surpasses approximately $80\\%$. The target occupancy of $RO^{*} = 0.65$ or $65\\%$ is chosen to be within this therapeutic window, providing a high likelihood of antipsychotic effect while minimizing the risk of dose-limiting EPS. This is a particularly prudent strategy in treating first-episode psychosis, as patients are often more sensitive to side effects, and minimizing them is crucial for establishing long-term treatment adherence.\n\n### Calculation of the Daily Dose ($D$)\n\nThe solution proceeds in four steps:\n1.  Calculate the required average steady-state unbound brain concentration ($C_{u,brain,ss,avg}^{*}$) to achieve the target occupancy $RO^{*}$.\n2.  Calculate the corresponding average steady-state total plasma concentration ($C_{p,ss,avg}^{*}$).\n3.  Use the pharmacokinetic model to determine the dose ($D$) that will produce this plasma concentration.\n4.  Ensure all units are consistent and provide the final answer in the requested units and precision.\n\n**Step A: Determine the Required Unbound Brain Concentration**\nStarting from the Hill-Langmuir equation, we solve for the ligand concentration, $[L]$, which we denote as $C_{u,brain,ss,avg}^{*}$.\n$$RO^{*} = \\frac{C_{u,brain,ss,avg}^{*}}{K_d + C_{u,brain,ss,avg}^{*}}$$\n$$RO^{*} (K_d + C_{u,brain,ss,avg}^{*}) = C_{u,brain,ss,avg}^{*}$$\n$$RO^{*} K_d = C_{u,brain,ss,avg}^{*} (1 - RO^{*})$$\n$$C_{u,brain,ss,avg}^{*} = \\frac{RO^{*} \\times K_d}{1 - RO^{*}}$$\nSubstituting the given values $RO^{*} = 0.65$ and $K_d = 1.5\\,\\text{nM}$:\n$$C_{u,brain,ss,avg}^{*} = \\frac{0.65 \\times 1.5\\,\\text{nM}}{1 - 0.65} = \\frac{0.975\\,\\text{nM}}{0.35} \\approx 2.785714\\,\\text{nM}$$\n\n**Step B: Determine the Required Total Plasma Concentration**\nUsing the given relationship linking brain and plasma concentrations:\n$$C_{u,brain,ss,avg}^{*} = C_{p,ss,avg}^{*} \\times f_{u,p} \\times K_{p,uu}$$\nWe solve for the required average total plasma concentration, $C_{p,ss,avg}^{*}$.\n$$C_{p,ss,avg}^{*} = \\frac{C_{u,brain,ss,avg}^{*}}{f_{u,p} \\times K_{p,uu}}$$\nSubstituting the values $C_{u,brain,ss,avg}^{*} \\approx 2.785714\\,\\text{nM}$, $f_{u,p} = 0.12$, and $K_{p,uu} = 1.0$:\n$$C_{p,ss,avg}^{*} = \\frac{2.785714\\,\\text{nM}}{0.12 \\times 1.0} \\approx 23.214286\\,\\text{nM}$$\n\n**Step C: Determine the Required Daily Dose**\nFor a drug administered orally, the average steady-state plasma concentration in a one-compartment linear model is given by:\n$$C_{p,ss,avg} = \\frac{F \\times D}{\\text{Cl} \\times \\tau}$$\nwhere $D$ is the dose administered per interval $\\tau$. We solve for the dose $D$:\n$$D = \\frac{C_{p,ss,avg}^{*} \\times \\text{Cl} \\times \\tau}{F}$$\nIt is critical to ensure unit consistency. The dose $D$ must be a mass, while $C_{p,ss,avg}^{*}$ is a molar concentration. We must convert the molar concentration to a mass concentration using the molecular weight, $\\text{MW}$.\n\nFirst, let's calculate the required dosing rate in nanomoles per hour:\n$$ \\text{Dosing Rate (molar)} = C_{p,ss,avg}^{*} \\times \\text{Cl} \\approx (23.214286\\,\\text{nmol/L}) \\times (9\\,\\text{L/h}) \\approx 208.92857\\,\\text{nmol/h} $$\nThis is the systemic clearance rate. The administered dosing rate must account for bioavailability $F$.\n$$ \\frac{F \\times D_{molar}}{\\tau} = C_{p,ss,avg}^{*} \\times \\text{Cl} $$\n$$ D_{molar} = \\frac{C_{p,ss,avg}^{*} \\times \\text{Cl} \\times \\tau}{F} $$\n$$ D_{molar} = \\frac{(208.92857\\,\\text{nmol/h}) \\times (24\\,\\text{h})}{0.60} \\approx 8357.1428\\,\\text{nmol per day} $$\nNow, we convert this molar amount to a mass amount ($D_{mass}$) using $\\text{MW} = 375\\,\\text{g/mol}$.\n$$ D_{mass} = D_{molar} \\times \\text{MW} $$\n$$ D_{mass} \\approx (8357.1428 \\times 10^{-9}\\,\\text{mol}) \\times (375\\,\\text{g/mol}) \\approx 3.133928 \\times 10^{-3}\\,\\text{g} $$\nConverting grams to milligrams:\n$$ D = (3.133928 \\times 10^{-3}\\,\\text{g}) \\times (1000\\,\\text{mg/g}) \\approx 3.133928\\,\\text{mg} $$\nThe question asks for the dose in $\\text{mg/day}$. Since our dosing interval $\\tau$ was $24$ hours ($1$ day), this calculated dose is already per day.\n\n**Step D: Final Calculation and Rounding**\nCombining all steps into a single expression:\n$$ D (\\text{mg/day}) = \\frac{\\left( \\frac{RO^{*} \\times K_d}{1 - RO^{*}} \\right) \\times \\text{Cl} \\times \\tau}{f_{u,p} \\times K_{p,uu} \\times F} \\times \\text{MW} \\times 10^{-6} $$\nThe factor of $10^{-6}$ converts the final result from (nmol/L) * (L/h) * h * (g/mol) to mg. Specifically, nmol $\\to$ mol ($10^{-9}$) and g $\\to$ mg ($10^3$), for a net factor of $10^{-6}$.\n$$ D = \\frac{\\left( \\frac{0.65 \\times 1.5}{1 - 0.65} \\right) \\times 9 \\times 24}{0.12 \\times 1.0 \\times 0.60} \\times 375 \\times 10^{-6} $$\n$$ D = \\frac{2.785714... \\times 216}{0.072} \\times 375 \\times 10^{-6} $$\n$$ D = \\frac{601.714...}{0.072} \\times 375 \\times 10^{-6} $$\n$$ D = 8357.1428... \\times 375 \\times 10^{-6} = 3133928.57... \\times 10^{-6} = 3.133928...\\,\\text{mg/day} $$\nRounding to four significant figures, we get:\n$$ D \\approx 3.134\\,\\text{mg/day} $$", "answer": "$$\\boxed{3.134}$$", "id": "4756580"}]}